Thermo Fisher Scientific's $13.6 Billion Acquisition of Life Technologies Boosts Flagging M&A Numbers May 01, 2013 | Press Release
Burrill Securities Launches Institutional Breakthrough Series April 29, 2013 | Press Release
Big Biotech Outpaces Big Pharma, Burrill & Company says April 16, 2013 | Press ReleaseSee all News
Anton GuethSenior Advisor
Mr. Gueth began his management career in business and alliance development over 20 years ago at Eli Lilly and Company. His global experience spans the U.S., Europe, the Middle East and Africa. Before joining Burrill & Company, Mr. Gueth was an independent consultant for pharmaceutical and biotechnology clients in the areas of licensing, early-stage financing and alliance management. His clients included Baxter, Amgen, Boehringer Ingelheim, Schering-Plough and Schering AG, among others. While at Lilly, Mr. Gueth held multiple positions of increasing responsibility, concluding as Director of Alliance Management. In this role he led Lilly’s efforts to become “the pharmaceutical partner of choice”. Mr. Gueth is a member of the board of directors of Antares Pharma. He is also on the board of the California chapter of the American Liver Foundation. An author and lecturer, Mr. Gueth has contributed to industry reports from In Vivo and Ernst and Young as well as business texts on strategic alliances. Mr. Gueth received his master’s degree in public affairs from Indiana University and an M.S. in agricultural economics from Justus Liebig University in Germany.